Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 03, 2021 16:14 ET | Source: MediWound Ltd.

MediWound to Present at Upcoming Investor Conferences

YAVNE, Israel, Sept. 03, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for...
August 10, 2021 07:00 ET | Source: MediWound Ltd.

MediWound Reports Second Quarter Financial Results

Second Quarter Revenues of $6.1 Million - Increase of 50% Year-over-Year Positive Interim Assessment Outcome for EscharEx U.S. Phase II Clinical Study No Changes to Study Sample Size – No Safety...
August 02, 2021 16:05 ET | Source: MediWound Ltd.

MediWound to Report Second Quarter 2021 Financial Results and Host a Conference Call and Webcast on August 10, 2021

YAVNE, Israel, Aug. 02, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair...
July 28, 2021 07:00 ET | Source: MediWound Ltd.

MediWound Announces Positive Outcome of Interim Assessment for its EscharEx U.S. Phase 2 Adaptive Design Study

Independent Data Monitoring Committee Recommends Continuation of the Study withNo Changes to Study Sample Size No Safety Concerns Identified Full Study Enrollment Expected by Year-End 2021;...
July 26, 2021 07:00 ET | Source: MediWound Ltd.

MediWound Announces Initiation of U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma

Data Expected End of 2021 Phase II Investigator-Initiated Trial in Non-Melanoma Skin Cancers Running in Parallel YAVNE, Israel, July 26, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a...
July 20, 2021 07:00 ET | Source: MediWound Ltd.

MediWound Announces Positive Topline Results from Phase 3 Pediatric Study (CIDS) of NexoBrid for Eschar Removal of Severe Thermal Burns

YAVNE, Israel, July 20, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation bio-therapeutics solutions for tissue repair...
July 09, 2021 08:00 ET | Source: MediWound Ltd.

MediWound Announces Peer-Reviewed Paper Detailing EscharEx Phase 2 Randomized Control Trial Results Published in the Online Wound Repair and Regeneration Journal

Study Findings Demonstrate Strong Results in Debriding Venous Leg Ulcers and Diabetic Foot Ulcers Interim Assessment of Ongoing U.S. Phase II Adaptive Design Study in Venus Leg Ulcers Expected End of...
June 29, 2021 08:45 ET | Source: MediWound Ltd.

MediWound Receives Complete Response Letter from U.S. FDA for NexoBrid Biologics License Application

YAVNE, Israel, June 29, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation bio-therapeutics solutions for tissue repair...
June 09, 2021 16:30 ET | Source: MediWound Ltd.

MediWound Completes Patient Enrollment for Interim Assessment of its U.S. EscharEx Phase 2 Adaptive Design Study

YAVNE, Israel, June 09, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and...
June 07, 2021 07:00 ET | Source: MediWound Ltd.

MediWound Announces Peer-Reviewed Paper of a Case Series Report of Basal Cell Carcinoma Published in the Open Dermatology Journal

Findings Provide Preliminary Proof-of-Concept Phase I/II Clinical Study in Basal Cell Carcinoma Scheduled to Begin in Second Quarter 2021, with Data Expected by the End of 2021 ...